Nanodisc Inc. is a privately-held life science start-up created to commercialize its innovative nanoscale technology in the biopharmaceutical space. The primary focus of the Company is the development of Nanodiscs as a therapeutic and vaccine delivery platform. Corporate highlights include:

• Unique, proprietary Nanodisc platform for delivery, imaging and diagnostics, target discovery and validation, lead generation and optimization
• Pursuing multiple high-value drug and vaccine delivery applications characterized by substantial unmet need and market opportunity with clinical entry of first candidate anticipated in 2009
• Continued alliance development with "best-in-class" partners to advance discovery assets
• Experienced management team supported by advisors and consultants with substantial domain expertise
• Exclusive license from the University of Illinois with allowance and issuance on generic composition of matter patents and further IP development underway
• Funding from IllinoisVENTURES and the Illinois Emerging Technology Fund